Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Journal of Infectious Diseases |
Vol/bind | 222 |
Udgave nummer | 7 |
Sider (fra-til) | 1103-1107 |
Antal sider | 5 |
ISSN | 0022-1899 |
DOI | |
Status | Udgivet - 2020 |
Links
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454684/pdf/jiaa446.pdf
Forlagets udgivne version
ID: 258330405